A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma
European Journal of Cancer2015Vol. 51(4), pp. 522–532
Citations Over TimeTop 10% of 2015 papers
Manfred Westphal, Oliver Heese, Joachim P. Steinbach, Oliver Schnell, Gabriele Schackert, H. Maximilian Mehdorn, D. Schulz, Matthias Simon, Uwe Schlegel, Christian Senft, Karsten Geletneky, Christian Braun, Joachim Härtung, Dirk Reuter, Monika Warmuth Metz, F. Bach, Torsten Pietsch
Related Papers
- → Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin(2009)247 cited
- → Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma(2021)43 cited
- → <p>Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer</p>(2019)14 cited
- → Nimotuzumab combined with radiotherapy reduces primary tumor and nodal volume in advanced undifferentiated nasopharyngeal carcinoma(2009)6 cited
- Clinical Research Progress in Nimotuzumab Combination with Radiotherapy(2014)